Pemetrexed disodium heptahydrate, the chemical compound name is L-Glutamic acid, N- [4- [2-amino-4,7-dihydro-4-oxo-1H pyrrolo [2,3-d] pyrimidin-5-yl ) ethyl] benzoyl] -, disodium salt, heptahydrate. The color is white with the molecular formula C20H19N5Na2O6 • 7H2O and its molecular weight is 597.49. The structure of the Pemetrexed formula is like this:
Pemetrexed, marketed under the Alimta trade name, is an FDA-approved chemotherapy drug for malignant pleural mesothelioma therapy. French researchers reported at the second European Lung Cancer Conference that the first stage of clinical trials suggested that Pemetrexed was also well tolerated by using high doses combined with concurrent radiation therapy to improve effectiveness as a lung cancer treatment.
The first trial was performed using Pemetrexed along with cisplatin chemotherapy and radiotherapy in nine mesothelioma cancer patients with stage III non-small-cell lung cancer. A tenth patient is excluded due to progression of the disease. Seven of the remaining nine patients completed all four cycles of chemotherapy, and eight of them completed radiation therapy.
One patient receiving the highest dose of pemetrexed grade 4 had septic shock, the dose-limit showed toxicity. But overall, pemetrexed is tolerated well enough to increase the chances of killing cancer cells.
Reference
First trial of pemetrexed with radiation and chemo in lung cancer shows promising results - physorg
European Society for Medical Oncology
 |
| Penetrexed Molecular Compounds |
Pemetrexed, marketed under the Alimta trade name, is an FDA-approved chemotherapy drug for malignant pleural mesothelioma therapy. French researchers reported at the second European Lung Cancer Conference that the first stage of clinical trials suggested that Pemetrexed was also well tolerated by using high doses combined with concurrent radiation therapy to improve effectiveness as a lung cancer treatment.
The first trial was performed using Pemetrexed along with cisplatin chemotherapy and radiotherapy in nine mesothelioma cancer patients with stage III non-small-cell lung cancer. A tenth patient is excluded due to progression of the disease. Seven of the remaining nine patients completed all four cycles of chemotherapy, and eight of them completed radiation therapy.
One patient receiving the highest dose of pemetrexed grade 4 had septic shock, the dose-limit showed toxicity. But overall, pemetrexed is tolerated well enough to increase the chances of killing cancer cells.
Reference
First trial of pemetrexed with radiation and chemo in lung cancer shows promising results - physorg
European Society for Medical Oncology
EmoticonEmoticon